{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:21Z","timestamp":1792839861080,"version":"4.5.0"},"reference-count":235,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T00:00:00Z","timestamp":1385164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00415-013-7169-7","type":"journal-article","created":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T02:44:21Z","timestamp":1385088261000},"page":"1-16","source":"Crossref","is-referenced-by-count":501,"title":["Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)"],"prefix":"10.1007","volume":"261","author":[{"name":"Neuromyelitis Optica Study Group (NEMOS)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Trebst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Jarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schippling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Borisow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,23]]},"reference":[{"key":"7169_CR1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14","journal-title":"J Neuroinflammation"},{"key":"7169_CR2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00115-010-3192-4","volume":"82","author":"C Trebst","year":"2011","unstructured":"Trebst C, Berthele A, Jarius S, K\u00fcmpfel T, Schippling S, Wildemann B, Wilke C (2011) Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group. Nervenarzt 82:768\u2013777","journal-title":"Nervenarzt"},{"key":"7169_CR3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"DJ Kimbrough","year":"2012","unstructured":"Kimbrough DJ, Fujihara K, Jacob A et al (2012) Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1:180\u2013187","journal-title":"Mult Scler Relat Disord"},{"key":"7169_CR4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17:1019\u20131032","journal-title":"Eur J Neurol"},{"key":"7169_CR5","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1212\/WNL.0b013e31823dc535","volume":"77","author":"TF Scott","year":"2011","unstructured":"Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG (2011) Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 77:2128\u20132134","journal-title":"Neurology"},{"key":"7169_CR6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00115-007-2262-8","volume":"78","author":"S Jarius","year":"2007","unstructured":"Jarius S, Wildemann B (2007) Neuromyelitis optica. Nervenarzt 78:1365\u20131377","journal-title":"Nervenarzt"},{"key":"7169_CR7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53:1107\u20131114","journal-title":"Neurology"},{"key":"7169_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","volume":"10","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B (2013) The history of neuromyelitis optica. J Neuroinflammation 10:8","journal-title":"J Neuroinflammation"},{"key":"7169_CR9","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00415-011-6355-8","volume":"259","author":"S Jarius","year":"2012","unstructured":"Jarius S, Wildemann B (2012) The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol 259:1354\u20131357","journal-title":"J Neurol"},{"key":"7169_CR10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jns.2011.09.025","volume":"313","author":"S Jarius","year":"2012","unstructured":"Jarius S, Wildemann B (2012) \u201cNoteomielite\u201d accompanied by acute amaurosis (1844). An early case of neuromyelitis optica. J Neurol Sci 313:182\u2013184","journal-title":"J Neurol Sci"},{"key":"7169_CR11","doi-asserted-by":"crossref","first-page":"e6430","DOI":"10.1136\/bmj.e6430","volume":"345","author":"S Jarius","year":"2012","unstructured":"Jarius S, Wildemann B (2012) An early British case of neuromyelitis optica (1850). BMJ 345:e6430","journal-title":"BMJ"},{"key":"7169_CR12","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/1352458511411758","volume":"17","author":"S Jarius","year":"2011","unstructured":"Jarius S, Wildemann B (2011) An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler 17:1384\u20131386","journal-title":"Mult Scler"},{"key":"7169_CR13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00415-012-6594-3","volume":"260","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B (2013) On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol 260:100\u2013104","journal-title":"J Neurol"},{"key":"7169_CR14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.410340211","volume":"34","author":"RN Mandler","year":"1993","unstructured":"Mandler RN, Davis LE, Jeffery DR, Kornfeld M (1993) Devic\u2019s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 34:162\u2013168","journal-title":"Ann Neurol"},{"key":"7169_CR15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 125:1450\u20131461","journal-title":"Brain"},{"key":"7169_CR16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2990.2010.01105.x","volume":"36","author":"D-H Lee","year":"2010","unstructured":"Lee D-H, Metz I, Berthele A, Stadelmann C, Br\u00fcck W, Linker RA, Gold R, Schroeder A (2010) Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol Appl Neurobiol 36:685\u2013687","journal-title":"Neuropathol Appl Neurobiol"},{"key":"7169_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473\u2013477","journal-title":"J Exp Med"},{"key":"7169_CR18","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"key":"7169_CR19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","volume":"4","author":"S Jarius","year":"2008","unstructured":"Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4:202\u2013214","journal-title":"Nat Clin Pract Neurol"},{"key":"7169_CR20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","volume":"6","author":"S Jarius","year":"2010","unstructured":"Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383\u2013392","journal-title":"Nat Rev Neurol"},{"key":"7169_CR21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-2094-5-22","volume":"5","author":"DJ Graber","year":"2008","unstructured":"Graber DJ, Levy M, Kerr D, Wade WF (2008) Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 5:22","journal-title":"J Neuroinflammation"},{"key":"7169_CR22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617\u2013629","journal-title":"Ann Neurol"},{"key":"7169_CR23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630\u2013643","journal-title":"Ann Neurol"},{"key":"7169_CR24","doi-asserted-by":"crossref","first-page":"e27412","DOI":"10.1371\/journal.pone.0027412","volume":"6","author":"J Ratelade","year":"2011","unstructured":"Ratelade J, Bennett JL, Verkman AS (2011) Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS One 6:e27412","journal-title":"PLoS One"},{"key":"7169_CR25","doi-asserted-by":"crossref","first-page":"e10455","DOI":"10.1371\/journal.pone.0010455","volume":"5","author":"S Mader","year":"2010","unstructured":"Mader S, Lutterotti A, Di Pauli F et al (2010) Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One 5:e10455","journal-title":"PLoS One"},{"key":"7169_CR26","doi-asserted-by":"crossref","first-page":"e15050","DOI":"10.1371\/journal.pone.0015050","volume":"5","author":"PA Nelson","year":"2010","unstructured":"Nelson PA, Khodadoust M, Prodhomme T, Spencer C, Patarroyo JC, Varrin-Doyer M, Ho JD, Stroud RM, Zamvil SS (2010) Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One 5:e15050","journal-title":"PLoS One"},{"key":"7169_CR27","doi-asserted-by":"crossref","first-page":"e16083","DOI":"10.1371\/journal.pone.0016083","volume":"6","author":"SR Kalluri","year":"2011","unstructured":"Kalluri SR, Rothhammer V, Staszewski O, Srivastava R, Petermann F, Prinz M, Hemmer B, Korn T (2011) Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One 6:e16083","journal-title":"PLoS One"},{"key":"7169_CR28","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"7169_CR29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/1352458508096878","volume":"14","author":"DH Miller","year":"2008","unstructured":"Miller DH, Weinshenker BG, Filippi M et al (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14:1157\u20131174","journal-title":"Mult Scler"},{"key":"7169_CR30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805\u2013815","journal-title":"Lancet Neurol"},{"key":"7169_CR31","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00415-009-5171-x","volume":"256","author":"E Bizzoco","year":"2009","unstructured":"Bizzoco E, Lolli F, Repice AM et al (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256:1891\u20131898","journal-title":"J Neurol"},{"key":"7169_CR32","doi-asserted-by":"crossref","unstructured":"Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, Das K, Boggild M (2013) The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 260:2134\u20132137","DOI":"10.1007\/s00415-013-6926-y"},{"key":"7169_CR33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","volume":"76","author":"N Asgari","year":"2011","unstructured":"Asgari N, Lillevang ST, Skejoe HPB, Falah M, Stenager E, Kyvik KO (2011) A population-based study of neuromyelitis optica in Caucasians. Neurology 76:1589\u20131595","journal-title":"Neurology"},{"key":"7169_CR34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.045","volume":"286","author":"DM Wingerchuk","year":"2009","unstructured":"Wingerchuk DM (2009) Neuromyelitis optica: effect of gender. J Neurol Sci 286:18\u201323","journal-title":"J Neurol Sci"},{"key":"7169_CR35","first-page":"247","volume":"11","author":"F Barbieri","year":"1989","unstructured":"Barbieri F, Buscaino GA (1989) Neuromyelitis optica in the elderly. Acta Neurol (Napoli) 11:247\u2013251","journal-title":"Acta Neurol (Napoli)"},{"key":"7169_CR36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","volume":"70","author":"B Banwell","year":"2008","unstructured":"Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ (2008) Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 70:344\u2013352","journal-title":"Neurology"},{"key":"7169_CR37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","volume":"71","author":"A McKeon","year":"2008","unstructured":"McKeon A, Lennon VA, Lotze T et al (2008) CNS aquaporin-4 autoimmunity in children. Neurology 71:93\u2013100","journal-title":"Neurology"},{"key":"7169_CR38","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1542\/peds.2007-2758","volume":"122","author":"TE Lotze","year":"2008","unstructured":"Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV (2008) Spectrum of pediatric neuromyelitis optica. Pediatrics 122:e1039\u2013e1047","journal-title":"Pediatrics"},{"key":"7169_CR39","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00415-009-5288-y","volume":"256","author":"R Bergamaschi","year":"2009","unstructured":"Bergamaschi R, Jarius S, Robotti M, Pichiecchio A, Wildemann B, Meola G (2009) Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol 256:2097\u20132099","journal-title":"J Neurol"},{"key":"7169_CR40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/jnnp.2007.143263","volume":"79","author":"S Jarius","year":"2008","unstructured":"Jarius S, Jacob S, Waters P, Jacob A, Littleton E, Vincent A (2008) Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. J Neurol Neurosurg Psychiatr 79:1084","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jns.2008.06.038","volume":"275","author":"CSK Kay","year":"2008","unstructured":"Kay CSK, Scola RH, Lorenzoni PJ, Jarius S, Arruda WO, Werneck LC (2008) NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci 275:148\u2013150","journal-title":"J Neurol Sci"},{"key":"7169_CR42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.21197","volume":"39","author":"A McKeon","year":"2009","unstructured":"McKeon A, Lennon VA, Jacob A et al (2009) Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 39:87\u201390","journal-title":"Muscle Nerve"},{"key":"7169_CR43","first-page":"78","volume":"65","author":"SJ Pittock","year":"2008","unstructured":"Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Z\u00e9phir H, Moder K, Weinshenker BG (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65:78\u201383","journal-title":"Arch Neurol"},{"key":"7169_CR44","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/art.27337","volume":"62","author":"K-P Wandinger","year":"2010","unstructured":"Wandinger K-P, Stangel M, Witte T, Venables P, Charles P, Jarius S, Wildemann B, Probst C, Iking-Konert C, Schneider M (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 62:1198\u20131200","journal-title":"Arthritis Rheum"},{"key":"7169_CR45","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/1352458511403958","volume":"17","author":"S Jarius","year":"2011","unstructured":"Jarius S, Jacobi C, de Seze J et al (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 17:1067\u20131073","journal-title":"Mult Scler"},{"key":"7169_CR46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00296-011-2176-4","volume":"33","author":"J Z\u00e1vada","year":"2013","unstructured":"Z\u00e1vada J, Nytrov\u00e1 P, Wandinger KP, Jarius S, Svobodov\u00e1 R, Probst C, Peterov\u00e1 V, Tegzov\u00e1 D, Pavelka K, Vencovsk\u00fd J (2013) Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatol Int 33:259\u2013263","journal-title":"Rheumatol Int"},{"key":"7169_CR47","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458511431728","volume":"18","author":"S Jarius","year":"2012","unstructured":"Jarius S, Paul F, Franciotta D et al (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 18:1135\u20131143","journal-title":"Mult Scler"},{"key":"7169_CR48","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","volume":"82","author":"A Nagaishi","year":"2011","unstructured":"Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, Nishizawa M, Sakimura K, Tanaka K (2011) Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatr 82:1360\u20131364","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archneur.63.6.851","volume":"63","author":"I Kister","year":"2006","unstructured":"Kister I, Gulati S, Boz C, Bergamaschi R, Piccolo G, Piccolo G, Oger J, Swerdlow ML (2006) Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 63:851\u2013856","journal-title":"Arch Neurol"},{"key":"7169_CR50","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/01.wnl.0000234142.41728.a0","volume":"67","author":"M Gotkine","year":"2006","unstructured":"Gotkine M, Fellig Y, Abramsky O (2006) Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 67:881\u2013883","journal-title":"Neurology"},{"key":"7169_CR51","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archneurol.2011.200","volume":"68","author":"A Vaknin-Dembinsky","year":"2011","unstructured":"Vaknin-Dembinsky A, Abramsky O, Petrou P, Ben-Hur T, Gotkine M, Brill L, Brenner T, Argov Z, Karussis D (2011) Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle? Arch Neurol 68:1557\u20131561","journal-title":"Arch Neurol"},{"key":"7169_CR52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","volume":"18","author":"DM Wingerchuk","year":"2012","unstructured":"Wingerchuk DM, Weinshenker BG (2012) The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 18:5\u201310","journal-title":"Mult Scler"},{"key":"7169_CR53","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834\u20131849","journal-title":"Brain"},{"key":"7169_CR54","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1007\/s00415-013-7031-y","volume":"260","author":"YD Fragoso","year":"2013","unstructured":"Fragoso YD, Adoni T, Bichuetti DB, Brooks JBB, Ferreira MLB, Oliveira EML, Oliveira CLS, Ribeiro SBF, Silva AE, Siquineli F (2013) Neuromyelitis optica and pregnancy. J Neurol 260:2614\u20132619","journal-title":"J Neurol"},{"key":"7169_CR55","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1212\/WNL.0b013e31824c466f","volume":"78","author":"B Bourre","year":"2012","unstructured":"Bourre B, Marignier R, Z\u00e9phir H et al (2012) Neuromyelitis optica and pregnancy. Neurology 78:875\u2013879","journal-title":"Neurology"},{"key":"7169_CR56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.38.2.180","volume":"38","author":"DW Paty","year":"1988","unstructured":"Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purves SJ, Low MD, Brandejs V (1988) MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180\u2013185","journal-title":"Neurology"},{"key":"7169_CR57","doi-asserted-by":"crossref","first-page":"e22766","DOI":"10.1371\/journal.pone.0022766","volume":"6","author":"Z Lu","year":"2011","unstructured":"Lu Z, Zhang B, Qiu W, Kang Z, Shen L, Long Y, Huang J, Hu X (2011) Comparative brain stem lesions on MRI of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. PLoS One 6:e22766","journal-title":"PLoS One"},{"key":"7169_CR58","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ana.22121","volume":"68","author":"M Apiwattanakul","year":"2010","unstructured":"Apiwattanakul M, Popescu BF, Matiello M, Weinshenker BG, Lucchinetti CF, Lennon VA, McKeon A, Carpenter AF, Miller GM, Pittock SJ (2010) Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 68:757\u2013761","journal-title":"Ann Neurol"},{"key":"7169_CR59","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","volume":"76","author":"BFG Popescu","year":"2011","unstructured":"Popescu BFG, Lennon VA, Parisi JE et al (2011) Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 76:1229\u20131237","journal-title":"Neurology"},{"key":"7169_CR60","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","volume":"65","author":"T Misu","year":"2005","unstructured":"Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y (2005) Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65:1479\u20131482","journal-title":"Neurology"},{"key":"7169_CR61","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/jnnp.2008.145391","volume":"79","author":"T Takahashi","year":"2008","unstructured":"Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, Tobita M, Itoyama Y (2008) Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatr 79:1075\u20131078","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR62","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneurol.2009.264","volume":"66","author":"T Kanbayashi","year":"2009","unstructured":"Kanbayashi T, Shimohata T, Nakashima I, Yaguchi H, Yabe I, Nishizawa M, Shimizu T, Nishino S (2009) Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 66:1563\u20131566","journal-title":"Arch Neurol"},{"key":"7169_CR63","first-page":"1355","volume":"69","author":"K Suzuki","year":"2012","unstructured":"Suzuki K, Nakamura T, Hashimoto K, Miyamoto M, Komagamine T, Nagashima T, Izawa N, Kanbayashi T, Takahashi T, Hirata K (2012) Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol 69:1355\u20131359","journal-title":"Arch Neurol"},{"key":"7169_CR64","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","volume":"72","author":"SM Maga\u00f1a","year":"2009","unstructured":"Maga\u00f1a SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, Shuster E, Kantarci OH, Lucchinetti CF, Weinshenker BG (2009) Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 72:712\u2013717","journal-title":"Neurology"},{"key":"7169_CR65","doi-asserted-by":"crossref","unstructured":"Schmidt F, \u00d6nder G, Jarius S, Wildemann B, Ruprecht K, Paul F, Harms L (2013) Olfactory dysfunction in patients with neuromyelitis optica. Multiple Sclerosis International: ID 654501","DOI":"10.1155\/2013\/654501"},{"key":"7169_CR66","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.4049\/jimmunol.1301483","volume":"191","author":"S Saadoun","year":"2013","unstructured":"Saadoun S, Waters P, Leite MI, Bennett JL, Vincent A, Papadopoulos MC (2013) Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol 191:2999\u20133005","journal-title":"J Immunol"},{"key":"7169_CR67","doi-asserted-by":"crossref","first-page":"b4026","DOI":"10.1136\/bmj.b4026","volume":"339","author":"R Reuss","year":"2009","unstructured":"Reuss R, Rommer PS, Br\u00fcck W et al (2009) A woman with acute myelopathy in pregnancy: case outcome. BMJ 339:b4026","journal-title":"BMJ"},{"key":"7169_CR68","unstructured":"Reuss R, Rommer P, Br\u00fcck W, Jarius S, Bolz M, Zettl UK (2010) Anti-AQP4 ab might be relevant in pregnancy. BMJ reply"},{"key":"7169_CR69","author":"J Cosgrove","year":"2013","unstructured":"Cosgrove J, Alli S, Ramadan H, Ford HL (2013) Myocarditis and diffuse skeletal muscle oedema: new features of neuromyelitis optica spectrum disorder? A case report. Mult Scler. doi: 10.1177\/1352458513495939","journal-title":"Mult Scler"},{"key":"7169_CR70","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2169\/internalmedicine.51.7898","volume":"51","author":"S Deguchi","year":"2012","unstructured":"Deguchi S, Deguchi K, Sato K et al (2012) HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica. Intern Med 51:2617\u20132620","journal-title":"Intern Med"},{"key":"7169_CR71","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1212\/WNL.0b013e3182698d39","volume":"79","author":"M Filippo Di","year":"2012","unstructured":"Di Filippo M, Franciotta D, Massa R et al (2012) Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology 79:1182\u20131184","journal-title":"Neurology"},{"key":"7169_CR72","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1212\/WNL.0b013e3181dd445b","volume":"74","author":"N Suzuki","year":"2010","unstructured":"Suzuki N, Takahashi T, Aoki M et al (2010) Neuromyelitis optica preceded by hyperCKemia episode. Neurology 74:1543\u20131545","journal-title":"Neurology"},{"key":"7169_CR73","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00415-012-6755-4","volume":"260","author":"S Jarius","year":"2013","unstructured":"Jarius S, Lauda F, Wildemann B, Tumani H (2013) Steroid-responsive hearing impairment in NMO-IgG\/aquaporin-4-antibody-positive neuromyelitis optica. J Neurol 260:663\u2013664","journal-title":"J Neurol"},{"key":"7169_CR74","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","volume":"298","author":"S Jarius","year":"2010","unstructured":"Jarius S, Frederikson J, Waters P et al (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298:158\u2013162","journal-title":"J Neurol Sci"},{"key":"7169_CR75","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","volume":"70","author":"M Matiello","year":"2008","unstructured":"Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70:2197\u20132200","journal-title":"Neurology"},{"key":"7169_CR76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jnnp.2008.146894","volume":"81","author":"A Petzold","year":"2010","unstructured":"Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT (2010) Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatr 81:109\u2013111","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR77","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"BG Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566\u2013569","journal-title":"Ann Neurol"},{"key":"7169_CR78","first-page":"1026","volume":"69","author":"S-M Kim","year":"2012","unstructured":"Kim S-M, Go MJ, Sung J-J, Park KS, Lee K-W (2012) Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 69:1026\u20131031","journal-title":"Arch Neurol"},{"key":"7169_CR79","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","volume":"77","author":"Y Kanamori","year":"2011","unstructured":"Kanamori Y, Nakashima I, Takai Y, Nishiyama S, Kuroda H, Takahashi T, Kanaoka-Suzuki C, Misu T, Fujihara K, Itoyama Y (2011) Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 77:652\u2013658","journal-title":"Neurology"},{"key":"7169_CR80","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1001\/archneurol.2012.768","volume":"69","author":"P Qian","year":"2012","unstructured":"Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT (2012) Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 69:1482\u20131487","journal-title":"Arch Neurol"},{"key":"7169_CR81","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00415-012-6677-1","volume":"259","author":"S Jarius","year":"2012","unstructured":"Jarius S, Paul F, Ruprecht K, Wildemann B (2012) Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol 259:2743\u20132745","journal-title":"J Neurol"},{"key":"7169_CR82","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clineuro.2011.10.048","volume":"114","author":"S Jarius","year":"2012","unstructured":"Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B (2012) Antibodies to CV2\/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 114:331\u2013335","journal-title":"Clin Neurol Neurosurg"},{"key":"7169_CR83","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00415-010-5511-x","volume":"257","author":"SR Jaiser","year":"2010","unstructured":"Jaiser SR, Winston GP (2010) Copper deficiency myelopathy. J Neurol 257:869\u2013881","journal-title":"J Neurol"},{"key":"7169_CR84","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184","journal-title":"J Neuroinflammation"},{"key":"7169_CR85","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","volume":"69","author":"K Rostasy","year":"2012","unstructured":"Rostasy K, Mader S, Schanda K et al (2012) Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 69:752\u2013756","journal-title":"Arch Neurol"},{"key":"7169_CR86","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273\u20131277","journal-title":"Neurology"},{"key":"7169_CR87","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","volume":"9","author":"M Reindl","year":"2013","unstructured":"Reindl M, Di Pauli F, Rost\u00e1sy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9:455\u2013461","journal-title":"Nat Rev Neurol"},{"key":"7169_CR88","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","volume":"65","author":"P Waters","year":"2008","unstructured":"Waters P, Jarius S, Littleton E et al (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65:913\u2013919","journal-title":"Arch Neurol"},{"key":"7169_CR89","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2008.03.009","volume":"196","author":"S Hayakawa","year":"2008","unstructured":"Hayakawa S, Mori M, Okuta A et al (2008) Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 196:181\u2013187","journal-title":"J Neuroimmunol"},{"key":"7169_CR90","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.wnl.0000256822.01222.bd","volume":"68","author":"S Jarius","year":"2007","unstructured":"Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, Hohlfeld R, Vincent A (2007) NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68:1076\u20131077","journal-title":"Neurology"},{"key":"7169_CR91","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","volume":"291","author":"S Jarius","year":"2010","unstructured":"Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger KP (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52\u201356","journal-title":"J Neurol Sci"},{"key":"7169_CR92","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/archneurol.2010.269","volume":"67","author":"SR Kalluri","year":"2010","unstructured":"Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, Bennett JL, Berthele A, Hemmer B (2010) Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 67:1201\u20131208","journal-title":"Arch Neurol"},{"key":"7169_CR93","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1371\/journal.pmed.0040133","volume":"4","author":"F Paul","year":"2007","unstructured":"Paul F, Jarius S, Aktas O et al (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4:e133","journal-title":"PLoS Med"},{"key":"7169_CR94","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1620\/tjem.210.307","volume":"210","author":"T Takahashi","year":"2006","unstructured":"Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Ishii N, Itoyama Y (2006) Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 210:307\u2013313","journal-title":"Tohoku J Exp Med"},{"key":"7169_CR95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jns.2012.06.002","volume":"320","author":"S Jarius","year":"2012","unstructured":"Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K, Ringelstein M, Aktas O, Kristoferitsch W, Wildemann B (2012) Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 320:32\u201337","journal-title":"J Neurol Sci"},{"key":"7169_CR96","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458511424590","volume":"18","author":"W Kim","year":"2012","unstructured":"Kim W, Lee J-E, Li XF, Kim S-H, Han B-G, Lee BI, Kim JK, Choi K, Kim HJ (2012) Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler 18:578\u2013586","journal-title":"Mult Scler"},{"key":"7169_CR97","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","volume":"23","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B (2013) Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 23:661\u2013683","journal-title":"Brain Pathol"},{"key":"7169_CR98","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Fujihara K, Nakashima I et al (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130:1235\u20131243","journal-title":"Brain"},{"key":"7169_CR99","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1177\/1352458511412995","volume":"17","author":"IA Ketelslegers","year":"2011","unstructured":"Ketelslegers IA, Modderman PW, Vennegoor A, Killestein J, Hamann D, Hintzen RQ (2011) Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Mult Scler 17:1527\u20131530","journal-title":"Mult Scler"},{"key":"7169_CR100","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131:3072\u20133080","journal-title":"Brain"},{"key":"7169_CR101","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jns.2008.08.015","volume":"276","author":"K Heerlein","year":"2009","unstructured":"Heerlein K, Jarius S, Jacobi C, Rohde S, Storch-Hagenlocher B, Wildemann B (2009) Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J Neurol Sci 276:184\u2013186","journal-title":"J Neurol Sci"},{"key":"7169_CR102","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310\u20131315","journal-title":"Neurology"},{"key":"7169_CR103","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1515\/CCLM.2010.127","volume":"48","author":"S Jarius","year":"2010","unstructured":"Jarius S, Franciotta D, Bergamaschi R, Wildemann B, Wandinger K-P (2010) Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 48:659\u2013663","journal-title":"Clin Chem Lab Med"},{"key":"7169_CR104","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","volume":"7","author":"S Jarius","year":"2010","unstructured":"Jarius S, Franciotta D, Paul F et al (2010) Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 7:52","journal-title":"J Neuroinflammation"},{"key":"7169_CR105","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1212\/01.wnl.0000345066.57745.50","volume":"72","author":"EC Klawiter","year":"2009","unstructured":"Klawiter EC, Alvarez E 3rd, Xu J, Paciorkowski AR, Zhu L, Parks BJ, Cross AH, Naismith RT (2009) NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 72:1101\u20131103","journal-title":"Neurology"},{"key":"7169_CR106","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1515\/CCLM.2011.717","volume":"49","author":"S Jarius","year":"2011","unstructured":"Jarius S, Wildemann B (2011) Effect of storage conditions and freeze\/thaw cycles on aquaporin-4 antibody (NMO-IgG) serum levels. Clin Chem Lab Med 49:2121\u20132122","journal-title":"Clin Chem Lab Med"},{"key":"7169_CR107","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"PJ Waters","year":"2012","unstructured":"Waters PJ, McKeon A, Leite MI et al (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78:665\u2013671 discussion 669","journal-title":"Neurology"},{"key":"7169_CR108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(02)00043-6","volume":"197","author":"J Seze De","year":"2002","unstructured":"De Seze J, Stojkovic T, Ferriby D, Gauvrit J-Y, Montagne C, Mounier-Vehier F, Verier A, Pruvo J-P, Hache J-C, Vermersch P (2002) Devic\u2019s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 197:57\u201361","journal-title":"J Neurol Sci"},{"key":"7169_CR109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","volume":"251","author":"A Ghezzi","year":"2004","unstructured":"Ghezzi A, Bergamaschi R, Martinelli V et al (2004) Clinical characteristics, course and prognosis of relapsing Devic\u2019s Neuromyelitis Optica. J Neurol 251:47\u201352","journal-title":"J Neurol"},{"key":"7169_CR110","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.60.4.382","volume":"60","author":"JI O\u2019Riordan","year":"1996","unstructured":"O\u2019Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, McDonald WI, Miller DH (1996) Clinical, CSF, and MRI findings in Devic\u2019s neuromyelitis optica. J Neurol Neurosurg Psychiatr 60:382\u2013387","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR111","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius S, Paul F, Franciotta D et al (2011) Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306:82\u201390","journal-title":"J Neurol Sci"},{"key":"7169_CR112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10072-008-0002-x","volume":"30","author":"D Lepur","year":"2009","unstructured":"Lepur D, Peterkovi\u0107 V, Kalabri\u0107-Lepur N (2009) Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis. Neurol Sci 30:51\u201354","journal-title":"Neurol Sci"},{"key":"7169_CR113","doi-asserted-by":"crossref","unstructured":"Jarius S, Wildemann B (2013) Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: A potential link. Med Hypotheses. doi: 10.1016\/j.mehy.2013.10.011","DOI":"10.1016\/j.mehy.2013.10.011"},{"key":"7169_CR114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1191\/1352458504ms988oa","volume":"10","author":"R Bergamaschi","year":"2004","unstructured":"Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, Romani A, Cosi V (2004) Oligoclonal bands in Devic\u2019s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 10:2\u20134","journal-title":"Mult Scler"},{"key":"7169_CR115","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/jnnp.2007.133330","volume":"79","author":"S Jarius","year":"2008","unstructured":"Jarius S, Franciotta D, Bergamaschi R et al (2008) Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatr 79:1134\u20131136","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR116","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","volume":"16","author":"A Uzawa","year":"2010","unstructured":"Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, Taniguchi J, Kuwabara S (2010) Cytokine and chemokine profiles in neuromyelitis optica: signifiance of interleukin-6. Mult Scler 16:1443\u20131452","journal-title":"Mult Scler"},{"key":"7169_CR117","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","volume":"120","author":"S I\u00e7\u00f6z","year":"2010","unstructured":"I\u00e7\u00f6z S, T\u00fcz\u00fcn E, K\u00fcrt\u00fcnc\u00fc M, Durmu\u015f H, Mutlu M, Eraksoy M, Akman-Demir G (2010) Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 120:71\u201375","journal-title":"Int J Neurosci"},{"key":"7169_CR118","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","volume":"19","author":"H Wang","year":"2012","unstructured":"Wang H, Wang K, Zhong X, Dai Y, Qiu W, Wu A, Hu X (2012) Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation 19:304\u2013308","journal-title":"Neuroimmunomodulation"},{"key":"7169_CR119","doi-asserted-by":"crossref","first-page":"e23489","DOI":"10.1371\/journal.pone.0023489","volume":"6","author":"M Storoni","year":"2011","unstructured":"Storoni M, Petzold A, Plant GT (2011) The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis. PLoS One 6:e23489","journal-title":"PLoS One"},{"key":"7169_CR120","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/brain\/awf165","volume":"125","author":"A Petzold","year":"2002","unstructured":"Petzold A, Eikelenboom MJ, Gveric D et al (2002) Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125:1462\u20131473","journal-title":"Brain"},{"key":"7169_CR121","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","volume":"80","author":"T Misu","year":"2009","unstructured":"Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y (2009) Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatr 80:575\u2013577","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR122","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1620\/tjem.215.55","volume":"215","author":"R Takano","year":"2008","unstructured":"Takano R, Misu T, Takahashi T, Izumiyama M, Fujihara K, Itoyama Y (2008) A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med 215:55\u201359","journal-title":"Tohoku J Exp Med"},{"key":"7169_CR123","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","volume":"75","author":"R Takano","year":"2010","unstructured":"Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y (2010) Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75:208\u2013216","journal-title":"Neurology"},{"key":"7169_CR124","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","volume":"421","author":"A Uzawa","year":"2013","unstructured":"Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, Ito S, Nomura F, Kuwabara S (2013) Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 421:181\u2013183","journal-title":"Clin Chim Acta"},{"key":"7169_CR125","author":"M Ringelstein","year":"2013","unstructured":"Ringelstein M, Kleiter I, Ayzenberg I et al (2013) Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler. doi: 10.1177\/1352458513503053","journal-title":"Mult Scler"},{"key":"7169_CR126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1352458512447597","volume":"19","author":"SP Neto","year":"2013","unstructured":"Neto SP, Alvarenga RMP, Vasconcelos CCF, Alvarenga MP, Pinto LC, Pinto VLR (2013) Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica. Mult Scler 19:173\u2013178","journal-title":"Mult Scler"},{"issue":"Suppl 4","key":"7169_CR127","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.1007\/s10072-004-0344-y","volume":"25","author":"M Filippi","year":"2004","unstructured":"Filippi M, Rocca MA (2004) MR imaging of Devic\u2019s neuromyelitis optica. Neurol Sci 25(Suppl 4):S371\u2013S373","journal-title":"Neurol Sci"},{"key":"7169_CR128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1352458510382685","volume":"17","author":"BC Lim","year":"2011","unstructured":"Lim BC, Hwang H, Kim KJ, Hwang YS, Cheon J-E, Kim I-O, Kim HJ, Chae J-H (2011) Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. Mult Scler 17:67\u201373","journal-title":"Mult Scler"},{"key":"7169_CR129","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00330-009-1425-3","volume":"19","author":"W Krampla","year":"2009","unstructured":"Krampla W, Aboul-Enein F, Jecel J, Lang W, Fertl E, Hruby W, Kristoferitsch W (2009) Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol 19:2535\u20132543","journal-title":"Eur Radiol"},{"key":"7169_CR130","doi-asserted-by":"crossref","unstructured":"Ringelstein M, Metz I, Ruprecht K, Koch A, Rappold J, Ingwersen J, Mathys C, Jarius S, Bruck W, Hartung HP, Paul F, Aktas O (2013) Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler. doi: 10.1177\/1352458513510981","DOI":"10.1177\/1352458513510981"},{"key":"7169_CR131","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","volume":"63","author":"SJ Pittock","year":"2006","unstructured":"Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63:390\u2013396","journal-title":"Arch Neurol"},{"key":"7169_CR132","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","volume":"80","author":"L Matthews","year":"2013","unstructured":"Matthews L, Marasco R, Jenkinson M et al (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80:1330\u20131337","journal-title":"Neurology"},{"key":"7169_CR133","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/WNL.0b013e3182648bc8","volume":"79","author":"T Sinnecker","year":"2012","unstructured":"Sinnecker T, D\u00f6rr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, Br\u00fcck W, Niendorf T, Wuerfel J, Paul F (2012) Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 79:708\u2013714","journal-title":"Neurology"},{"key":"7169_CR134","first-page":"398259","volume":"2013","author":"I Kister","year":"2013","unstructured":"Kister I, Herbert J, Zhou Y, Ge Y (2013) Ultrahigh-Field MR (7 T) Imaging of brain lesions in Neuromyelitis Optica. Mult Scler Int 2013:398259","journal-title":"Mult Scler Int"},{"key":"7169_CR135","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1352458509103301","volume":"15","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Misu T, Fujihara K, Miyazawa I, Nakashima I, Takahashi T, Watanabe S, Itoyama Y (2009) Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 15:695\u2013700","journal-title":"Mult Scler"},{"key":"7169_CR136","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","volume":"63","author":"SJ Pittock","year":"2006","unstructured":"Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63:964\u2013968","journal-title":"Arch Neurol"},{"key":"7169_CR137","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000334129","volume":"3","author":"H Nakajima","year":"2011","unstructured":"Nakajima H, Fujiki Y, Ito T, Kitaoka H, Takahashi T (2011) Anti-aquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation. Case Rep Neurol 3:263\u2013267","journal-title":"Case Rep Neurol"},{"key":"7169_CR138","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/jnnp.2005.080390","volume":"77","author":"I Nakashima","year":"2006","unstructured":"Nakashima I, Fujihara K, Miyazawa I et al (2006) Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatr 77:1073\u20131075","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR139","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1191\/1352458505ms1200cr","volume":"11","author":"AY Poppe","year":"2005","unstructured":"Poppe AY, Lapierre Y, Melan\u00e7on D, Lowden D, Wardell L, Fullerton LM, Bar-Or A (2005) Neuromyelitis optica with hypothalamic involvement. Mult Scler 11:617\u2013621","journal-title":"Mult Scler"},{"key":"7169_CR140","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1352458511431730","volume":"18","author":"P Banker","year":"2012","unstructured":"Banker P, Sonni S, Kister I, Loh JP, Lui YW (2012) Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler 18:1050\u20131053","journal-title":"Mult Scler"},{"key":"7169_CR141","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/1352458510376640","volume":"16","author":"W Kim","year":"2010","unstructured":"Kim W, Park MS, Lee SH, Kim S-H, Jung IJ, Takahashi T, Misu T, Fujihara K, Kim HJ (2010) Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 16:1229\u20131236","journal-title":"Mult Scler"},{"key":"7169_CR142","first-page":"735486","volume":"2012","author":"W Kim","year":"2012","unstructured":"Kim W, Kim S-H, Huh S-Y, Kim HJ (2012) Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012:735486","journal-title":"Mult Scler Int"},{"key":"7169_CR143","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/1352458510365156","volume":"16","author":"M Bock","year":"2010","unstructured":"Bock M, Brandt AU, D\u00f6rr J, Pfueller CF, Ohlraun S, Zipp F, Paul F (2010) Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. Mult Scler 16:893\u2013896","journal-title":"Mult Scler"},{"key":"7169_CR144","first-page":"530305","volume":"2012","author":"T Oberwahrenbrock","year":"2012","unstructured":"Oberwahrenbrock T, Schippling S, Ringelstein M et al (2012) Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012:530305","journal-title":"Mult Scler Int"},{"key":"7169_CR145","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1093\/brain\/awr095","volume":"134","author":"AU Brandt","year":"2011","unstructured":"Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, Martin R, Aktas O, Paul F, Schippling S (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 134:e193 author reply e194","journal-title":"Brain"},{"key":"7169_CR146","doi-asserted-by":"crossref","first-page":"e23024","DOI":"10.1371\/journal.pone.0023024","volume":"6","author":"S Stricker","year":"2011","unstructured":"Stricker S, Oberwahrenbrock T, Zimmermann H, Schroeter J, Endres M, Brandt AU, Paul F (2011) Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1. PLoS One 6:e23024","journal-title":"PLoS One"},{"key":"7169_CR147","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/1352458512457844","volume":"19","author":"H Zimmermann","year":"2013","unstructured":"Zimmermann H, Freing A, Kaufhold F et al (2013) Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler 19:443\u2013450","journal-title":"Mult Scler"},{"key":"7169_CR148","doi-asserted-by":"crossref","first-page":"e18132","DOI":"10.1371\/journal.pone.0018132","volume":"6","author":"J D\u00f6rr","year":"2011","unstructured":"D\u00f6rr J, Wernecke KD, Bock M, Gaede G, Wuerfel JT, Pfueller CF, Bellmann-Strobl J, Freing A, Brandt AU, Friedemann P (2011) Association of retinal and macular damage with brain atrophy in multiple sclerosis. PLoS One 6:e18132","journal-title":"PLoS One"},{"key":"7169_CR149","doi-asserted-by":"crossref","first-page":"e34891","DOI":"10.1371\/journal.pone.0034891","volume":"7","author":"P Albrecht","year":"2012","unstructured":"Albrecht P, M\u00fcller A-K, S\u00fcdmeyer M et al (2012) Optical coherence tomography in parkinsonian syndromes. PLoS One 7:e34891","journal-title":"PLoS One"},{"key":"7169_CR150","author":"T Oberwahrenbrock","year":"2013","unstructured":"Oberwahrenbrock T, Ringelstein M, Jentschke S et al (2013) Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler. doi: 10.1177\/1352458513489757","journal-title":"Mult Scler"},{"key":"7169_CR151","first-page":"869814","volume":"2011","author":"CF Pfueller","year":"2011","unstructured":"Pfueller CF, Paul F (2011) Imaging the visual pathway in neuromyelitis optica. Mult Scler Int 2011:869814","journal-title":"Mult Scler Int"},{"key":"7169_CR152","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WNO.0b013e31829f39f1","volume":"33","author":"DB Bichuetti","year":"2013","unstructured":"Bichuetti DB, de Camargo AS, Falc\u00e3o AB, Gon\u00e7alves FF, Tavares IM, de Oliveira EML (2013) The retinal nerve fiber layer of patients with neuromyelitis optica and chronic relapsing optic neuritis is more severely damaged than patients with multiple sclerosis. J Neuroophthalmol 33:220\u2013224","journal-title":"J Neuroophthalmol"},{"key":"7169_CR153","first-page":"920","volume":"65","author":"J Seze De","year":"2008","unstructured":"De Seze J, Blanc F, Jeanjean L et al (2008) Optical coherence tomography in neuromyelitis optica. Arch Neurol 65:920\u2013923","journal-title":"Arch Neurol"},{"key":"7169_CR154","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/01.wnl.0000345042.53843.d5","volume":"72","author":"RT Naismith","year":"2009","unstructured":"Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd J, Trinkaus K, Song S-K, Cross AH (2009) Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 72:1077\u20131082","journal-title":"Neurology"},{"key":"7169_CR155","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.0b013e3181af78b8","volume":"73","author":"JN Ratchford","year":"2009","unstructured":"Ratchford JN, Quigg ME, Conger A, Frohman T, Frohman E, Balcer LJ, Calabresi PA, Kerr DA (2009) Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73:302\u2013308","journal-title":"Neurology"},{"key":"7169_CR156","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/jnnp.2008.166207","volume":"80","author":"AJ Green","year":"2009","unstructured":"Green AJ, Cree BAC (2009) Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatr 80:1002\u20131005","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR157","doi-asserted-by":"crossref","unstructured":"Gelfand JM, Cree BA, Nolan R, Arnow S, Green AJ (2013) Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol pp 1\u20135","DOI":"10.1001\/jamaneurol.2013.1832"},{"key":"7169_CR158","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1212\/WNL.0b013e31828c2f7a","volume":"80","author":"ES Sotirchos","year":"2013","unstructured":"Sotirchos ES, Saidha S, Byraiah G et al (2013) In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology 80:1406\u20131414","journal-title":"Neurology"},{"key":"7169_CR159","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1177\/1352458513476562","volume":"19","author":"M Bouyon","year":"2013","unstructured":"Bouyon M, Collongues N, Z\u00e9phir H et al (2013) Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler 19:1320\u20131322","journal-title":"Mult Scler"},{"key":"7169_CR160","doi-asserted-by":"crossref","unstructured":"Schneider E, Zimmermann H, Oberwahrenbrock T et al (2013) Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One p e66151","DOI":"10.1371\/journal.pone.0066151"},{"key":"7169_CR161","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1756285611403646","volume":"4","author":"JCC Sa De","year":"2011","unstructured":"De Sa JCC, Airas L, Bartholome E et al (2011) Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord 4:139\u2013168","journal-title":"Ther Adv Neurol Disord"},{"key":"7169_CR162","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ncl.2011.01.008","volume":"29","author":"LM Samkoff","year":"2011","unstructured":"Samkoff LM, Goodman AD (2011) Symptomatic management in multiple sclerosis. Neurol Clin 29:449\u2013463","journal-title":"Neurol Clin"},{"key":"7169_CR163","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1352458512451659","volume":"19","author":"K-H Chang","year":"2013","unstructured":"Chang K-H, Lyu R-K, Chen C-M, Wu Y-R, Chang H-S, Huang C-C, Kuo H-C, Chu C-C, Hsu W-C, Ro L-S (2013) Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies. Mult Scler 19:299\u2013307","journal-title":"Mult Scler"},{"key":"7169_CR164","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","volume":"10","author":"DM Wingerchuk","year":"2008","unstructured":"Wingerchuk DM, Weinshenker BG (2008) Neuromyelitis optica. Curr Treat Options Neurol 10:55\u201366","journal-title":"Curr Treat Options Neurol"},{"key":"7169_CR165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","volume":"58","author":"M Keegan","year":"2002","unstructured":"Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58:143\u2013146","journal-title":"Neurology"},{"key":"7169_CR166","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","volume":"15","author":"M Bonnan","year":"2009","unstructured":"Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P (2009) Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15:487\u2013492","journal-title":"Mult Scler"},{"key":"7169_CR167","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-0404.2011.01612.x","volume":"126","author":"S Roesner","year":"2012","unstructured":"Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C (2012) Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand 126:103\u2013108","journal-title":"Acta Neurol Scand"},{"key":"7169_CR168","first-page":"787630","volume":"2012","author":"M Bonnan","year":"2012","unstructured":"Bonnan M, Cabre P (2012) Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012:787630","journal-title":"Mult Scler Int"},{"key":"7169_CR169","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","volume":"130","author":"H Merle","year":"2012","unstructured":"Merle H, Olindo S, Jeannin S et al (2012) Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 130:858\u2013862","journal-title":"Arch Ophthalmol"},{"key":"7169_CR170","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","volume":"68","author":"SM Maga\u00f1a","year":"2011","unstructured":"Maga\u00f1a SM, Keegan BM, Weinshenker BG et al (2011) Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 68:870\u2013878","journal-title":"Arch Neurol"},{"key":"7169_CR171","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"BG Weinshenker","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878\u2013886","journal-title":"Ann Neurol"},{"key":"7169_CR172","unstructured":"Nakashima I, Takahashi T, Nishiyama S, Kasahara S, Suzuki C, Misu T, Itoyama Y, Fuijihara K (2009) Plasma Exchange for Neuromyelitis Optica with Aquaporin-4 Antibody. Neurology 72:A187"},{"key":"7169_CR173","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0b013e3181b879be","volume":"73","author":"S Llufriu","year":"2009","unstructured":"Llufriu S, Castillo J, Blanco Y et al (2009) Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6\u00a0months. Neurology 73:949\u2013953","journal-title":"Neurology"},{"key":"7169_CR174","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","volume":"13","author":"S Watanabe","year":"2007","unstructured":"Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, Itoyama Y (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13:128\u2013132","journal-title":"Mult Scler"},{"key":"7169_CR175","author":"L Elsone","year":"2013","unstructured":"Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A (2013) Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. doi: 10.1177\/1352458513495938","journal-title":"Mult Scler"},{"key":"7169_CR176","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1212\/01.wnl.0000260970.63493.c8","volume":"68","author":"BM Greenberg","year":"2007","unstructured":"Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA (2007) Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 68:1614\u20131617","journal-title":"Neurology"},{"key":"7169_CR177","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","volume":"77","author":"C Costanzi","year":"2011","unstructured":"Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659\u2013666","journal-title":"Neurology"},{"key":"7169_CR178","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","volume":"67","author":"DB Bichuetti","year":"2010","unstructured":"Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67:1131\u20131136","journal-title":"Arch Neurol"},{"key":"7169_CR179","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","volume":"13","author":"S Watanabe","year":"2007","unstructured":"Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, Itoyama Y (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13:968\u2013974","journal-title":"Mult Scler"},{"key":"7169_CR180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/pgs.09.155","volume":"11","author":"JE Higgs","year":"2010","unstructured":"Higgs JE, Payne K, Roberts C, Newman WG (2010) Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11:177\u2013188","journal-title":"Pharmacogenomics"},{"key":"7169_CR181","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BAC Cree","year":"2005","unstructured":"Cree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270\u20131272","journal-title":"Neurology"},{"key":"7169_CR182","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443\u20131448","journal-title":"Arch Neurol"},{"key":"7169_CR183","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"S-H Kim","year":"2011","unstructured":"Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2\u00a0years. Arch Neurol 68:1412\u20131420","journal-title":"Arch Neurol"},{"key":"7169_CR184","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17:1225\u20131230","journal-title":"Mult Scler"},{"key":"7169_CR185","author":"S-H Kim","year":"2013","unstructured":"Kim S-H, Huh S-Y, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. doi: 10.1001\/jamaneurol.2013.3071","journal-title":"JAMA Neurol"},{"key":"7169_CR186","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","volume":"18","author":"BM Greenberg","year":"2012","unstructured":"Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E (2012) Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 18:1022\u20131026","journal-title":"Mult Scler"},{"key":"7169_CR187","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"C-S Yang","year":"2013","unstructured":"Yang C-S, Yang L, Li T et al (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81:710\u2013713","journal-title":"Neurology"},{"key":"7169_CR188","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66:1128\u20131133","journal-title":"Arch Neurol"},{"key":"7169_CR189","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/TP.0b013e31818b62c8","volume":"86","author":"RT Neff","year":"2008","unstructured":"Neff RT, Hurst FP, Falta EM, Bohen EM, Lentine KL, Dharnidharka VR, Agodoa LY, Jindal RM, Yuan CM, Abbott KC (2008) Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 86:1474\u20131478","journal-title":"Transplantation"},{"key":"7169_CR190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","volume":"31","author":"J Bakker","year":"2004","unstructured":"Bakker J, Metz L (2004) Devic\u2019s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31:265\u2013267","journal-title":"Can J Neurol Sci"},{"key":"7169_CR191","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","volume":"46","author":"K Okada","year":"2007","unstructured":"Okada K, Tsuji S, Tanaka K (2007) Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 46:1671\u20131672","journal-title":"Intern Med"},{"key":"7169_CR192","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","volume":"28","author":"MJ Magraner","year":"2012","unstructured":"Magraner MJ, Coret F, Casanova B (2012) The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 28:65\u201372","journal-title":"Neurologia"},{"key":"7169_CR193","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","volume":"68","author":"S-H Kim","year":"2011","unstructured":"Kim S-H, Kim W, Park MS, Sohn EH, Li XF, Kim HJ (2011) Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68:473\u2013479","journal-title":"Arch Neurol"},{"key":"7169_CR194","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","volume":"84","author":"P Cabre","year":"2013","unstructured":"Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D, Aegis of French National Observatory of Multiple Sclerosis (2013) Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatr 84:511\u2013516","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"7169_CR195","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1212\/WNL.0b013e3181b878f6","volume":"73","author":"J D\u00f6rr","year":"2009","unstructured":"D\u00f6rr J, Bitsch A, Schmailzl KJG et al (2009) Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 73:991\u2013993","journal-title":"Neurology"},{"key":"7169_CR196","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1756285611433318","volume":"5","author":"A Stroet","year":"2012","unstructured":"Stroet A, Hemmelmann C, Starck M et al (2012) Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord 5:75\u201379","journal-title":"Ther Adv Neurol Disord"},{"key":"7169_CR197","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1212\/WNL.0b013e318238ee00","volume":"77","author":"V Martinelli","year":"2011","unstructured":"Martinelli V, Cocco E, Capra R et al (2011) Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 77:1887\u20131895","journal-title":"Neurology"},{"key":"7169_CR198","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1191\/096120399678847696","volume":"8","author":"F Bonnet","year":"1999","unstructured":"Bonnet F, Merci\u00e9 P, Morlat P et al (1999) Devic\u2019s neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus 8:244\u2013247","journal-title":"Lupus"},{"key":"7169_CR199","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1191\/0961203306lu2265cr","volume":"15","author":"C Jacobi","year":"2006","unstructured":"Jacobi C, Stingele K, Kretz R, Hartmann M, Storch-Hagenlocher B, Breitbart A, Wildemann B (2006) Neuromyelitis optica (Devic\u2019s syndrome) as first manifestation of systemic lupus erythematosus. Lupus 15:107\u2013109","journal-title":"Lupus"},{"key":"7169_CR200","first-page":"172","volume":"35","author":"CC Mok","year":"2008","unstructured":"Mok CC, To CH, Mak A, Poon WL (2008) Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 35:172\u2013174","journal-title":"J Rheumatol"},{"key":"7169_CR201","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2169\/internalmedicine.52.7885","volume":"52","author":"H Yaguchi","year":"2013","unstructured":"Yaguchi H, Sakushima K, Takahashi I et al (2013) Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 52:969\u2013972","journal-title":"Intern Med"},{"key":"7169_CR202","doi-asserted-by":"crossref","unstructured":"Bichuetti DB, Oliveira EML, Boulos F de C, Gabbai AA (2012) Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 69:938\u2013939","DOI":"10.1001\/archneurol.2012.545"},{"key":"7169_CR203","first-page":"39","volume":"2","author":"A Minagar","year":"2000","unstructured":"Minagar A, Sheremara W (2000) Treatment of Devic\u2019s disease with methotrexate and prednisone. Int J MS Care 2:39\u201343","journal-title":"Int J MS Care"},{"key":"7169_CR204","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","volume":"13","author":"C Papeix","year":"2007","unstructured":"Papeix C, Vidal J-S, de Seze J et al (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13:256\u2013259","journal-title":"Mult Scler"},{"key":"7169_CR205","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","volume":"75","author":"J Shimizu","year":"2010","unstructured":"Shimizu J, Hatanaka Y, Hasegawa M et al (2010) IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75:1423\u20131427","journal-title":"Neurology"},{"key":"7169_CR206","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","volume":"67","author":"J Palace","year":"2010","unstructured":"Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67:1016\u20131017","journal-title":"Arch Neurol"},{"key":"7169_CR207","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","volume":"18","author":"S-H Kim","year":"2012","unstructured":"Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ (2012) Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 18:1480\u20131483","journal-title":"Mult Scler"},{"key":"7169_CR208","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","volume":"17","author":"A Uzawa","year":"2010","unstructured":"Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S (2010) Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 17:672\u2013676","journal-title":"Eur J Neurol"},{"key":"7169_CR209","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/j.1468-1331.2007.01807.x","volume":"14","author":"K Gartzen","year":"2007","unstructured":"Gartzen K, Limmroth V, Putzki N (2007) Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol 14:e12\u2013e13","journal-title":"Eur J Neurol"},{"key":"7169_CR210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-003-0979-2","volume":"250","author":"R Bergamaschi","year":"2003","unstructured":"Bergamaschi R, Uggetti C, Tonietti S, Egitto MG, Cosi V (2003) A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 250:359\u2013361","journal-title":"J Neurol"},{"key":"7169_CR211","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","volume":"84","author":"J Kitley","year":"2013","unstructured":"Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J (2013) Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 84:918\u2013921","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7169_CR212","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","volume":"69","author":"I Kleiter","year":"2012","unstructured":"Kleiter I, Hellwig K, Berthele A, K\u00fcmpfel T, Linker RA, Hartung H-P, Paul F, Aktas O (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69:239\u2013245","journal-title":"Arch Neurol"},{"key":"7169_CR213","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","volume":"18","author":"MH Barnett","year":"2012","unstructured":"Barnett MH, Prineas JW, Buckland ME, Parratt JDE, Pollard JD (2012) Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 18:108\u2013112","journal-title":"Mult Scler"},{"key":"7169_CR214","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/WNL.0b013e31826845fe","volume":"79","author":"A Jacob","year":"2012","unstructured":"Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, Tubridy N, Boggild M (2012) Does natalizumab therapy worsen neuromyelitis optica? Neurology 79:1065\u20131066","journal-title":"Neurology"},{"key":"7169_CR215","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","volume":"18","author":"J-H Min","year":"2012","unstructured":"Min J-H, Kim BJ, Lee KH (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 18:113\u2013115","journal-title":"Mult Scler"},{"key":"7169_CR216","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00415-012-6692-2","volume":"260","author":"T Kageyama","year":"2013","unstructured":"Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, Takahashi R, Kusunoki S, Matsumoto S, Kondo T (2013) Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 260:627\u2013634","journal-title":"J Neurol"},{"key":"7169_CR217","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1744-9987.2009.00780.x","volume":"13","author":"K Miyamoto","year":"2009","unstructured":"Miyamoto K, Kusunoki S (2009) Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13:505\u2013508","journal-title":"Ther Apher Dial"},{"key":"7169_CR218","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T (2011) Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108:3701\u20133706","journal-title":"Proc Natl Acad Sci USA"},{"key":"7169_CR219","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","volume":"23","author":"M Araki","year":"2013","unstructured":"Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T (2013) Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 23:827\u2013831","journal-title":"Mod Rheumatol"},{"key":"7169_CR220","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","volume":"70","author":"BC Kieseier","year":"2012","unstructured":"Kieseier BC, St\u00fcve O, Dehmel T et al (2012) Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 70:390\u2013393","journal-title":"JAMA Neurol"},{"key":"7169_CR221","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"I Ayzenberg","year":"2013","unstructured":"Ayzenberg I, Kleiter I, Schr\u00f6der A, Hellwig K, Chan A, Yamamura T, Gold R (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70:394\u2013397","journal-title":"JAMA Neurol"},{"key":"7169_CR222","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O\u2019Toole O, Wingerchuk DM (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12:554\u2013562","journal-title":"Lancet Neurol"},{"key":"7169_CR223","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1474-4422(13)70089-9","volume":"12","author":"F Paul","year":"2013","unstructured":"Paul F (2013) Hope for a rare disease: eculizumab in neuromyelitis optica. Lancet Neurol 12:529\u2013531","journal-title":"Lancet Neurol"},{"key":"7169_CR224","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Saadoun S, Phuan P-W, Lam C, Papadopoulos MC, Bennett JL, Verkman AS (2012) Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71:314\u2013322","journal-title":"Ann Neurol"},{"key":"7169_CR225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2013.03.003","volume":"260","author":"K Miyazaki","year":"2013","unstructured":"Miyazaki K, Abe Y, Iwanari H et al (2013) Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4. J Neuroimmunol 260:107\u2013116","journal-title":"J Neuroimmunol"},{"key":"7169_CR226","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","volume":"71","author":"S Saadoun","year":"2012","unstructured":"Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, Papadopoulos MC (2012) Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol 71:323\u2013333","journal-title":"Ann Neurol"},{"key":"7169_CR227","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","volume":"123","author":"H Zhang","year":"2013","unstructured":"Zhang H, Verkman AS (2013) Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 123:2306\u20132316","journal-title":"J Clin Invest"},{"key":"7169_CR228","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.113.086470","volume":"83","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip L, Asavapanumas N, Verkman AS (2013) Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase. Mol Pharmacol 83:1268\u20131275","journal-title":"Mol Pharmacol"},{"key":"7169_CR229","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ana.23741","volume":"73","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip L, Ratelade J, Zhang H, Verkman AS (2013) Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 73:77\u201385","journal-title":"Ann Neurol"},{"key":"7169_CR230","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archneurol.2011.38","volume":"68","author":"M Matiello","year":"2011","unstructured":"Matiello M, Pittock SJ, Porrata L, Weinshenker BG (2011) Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica. Arch Neurol 68:953\u2013955","journal-title":"Arch Neurol"},{"key":"7169_CR231","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/archneurol.2011.194","volume":"68","author":"P Qian","year":"2011","unstructured":"Qian P, Cross AH, Naismith RT (2011) Lack of response to monoclonal antibody therapy in neuromyelitis optica. Arch Neurol 68:1207\u20131209","journal-title":"Arch Neurol"},{"key":"7169_CR232","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1212\/WNL.0b013e318266fc2b","volume":"79","author":"A Vaknin-Dembinsky","year":"2012","unstructured":"Vaknin-Dembinsky A, Brill L, Kassis I, Petrou P, Ovadia H, Ben-Hur T, Abramsky O, Karussis D (2012) T-cell reactivity against AQP4 in neuromyelitis optica. Neurology 79:945\u2013946","journal-title":"Neurology"},{"key":"7169_CR233","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.23669","volume":"72","author":"HL Weiner","year":"2012","unstructured":"Weiner HL (2012) Role of T cells in neuromyelitis optica. Ann Neurol 72:6\u20138","journal-title":"Ann Neurol"},{"key":"7169_CR234","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1352458512440060","volume":"18","author":"K Herges","year":"2012","unstructured":"Herges K, de Jong BA, Kolkowitz I et al (2012) Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler 18:398\u2013408","journal-title":"Mult Scler"},{"key":"7169_CR235","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","volume":"11","author":"MC Papadopoulos","year":"2012","unstructured":"Papadopoulos MC, Verkman AS (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11:535\u2013544","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-013-7169-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-013-7169-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-013-7169-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T19:32:57Z","timestamp":1564860777000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-013-7169-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,23]]},"references-count":235,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["7169"],"URL":"https:\/\/doi.org\/10.1007\/s00415-013-7169-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,23]]}}}